title: Stanford V program for locally extensive and advanced Hodgkin lymphoma: the Memorial Sloan-Kettering Cancer Center experience.
abstract: BACKGROUND
  The Stanford group has reported excellent results with the Stanford V regimen for patients with bulky and/or advanced Hodgkin lymphoma (HL). However, Gobbi reported markedly inferior failure-free survival (FFS) comparing Stanford V to other regimens but included major deviations from the original program. We retrospectively examined whether treatment at our institution carefully following Stanford V guidelines would confirm the original Stanford outcome data.
  
  
  METHODS
  From June 1995 to May 2002, 126 patients with either locally extensive or advanced HL were treated with the 12-week Stanford V chemotherapy program followed by 36-Gy involved-field radiotherapy to sites initially > or =5 cm and/or to macroscopic splenic disease. Overall, 26% had stage IV disease and 20% had international prognostic score (IPS) > or =4. Overall survival (OS), disease-specific survival, progression-free survival (PFS), FFS, and freedom from second relapse (FF2R) were determined.
  
  
  RESULTS
  The 5- and 7-year OS were 90% and 88%, respectively. The 5-year FFS was 78%. IPS > or =4 was a significant independent predictor of worse OS and PFS. The FF2R was 64% at 3 years.
  
  
  CONCLUSIONS
  Stanford V with appropriate radiotherapy is a highly effective regimen for locally extensive and advanced HL.
authors.affiliation: From the Lymphoma Disease Management Team and Department of Radiation Oncology and Department of Radiation Oncology.
authors.forename: S M
authors.initials: SM
authors.lastname: Edwards-Bennett
authors.affiliation: Medicine.
authors.forename: L M
authors.initials: LM
authors.lastname: Jacks
authors.affiliation: Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: C H
authors.initials: CH
authors.lastname: Moskowitz
authors.affiliation: From the Lymphoma Disease Management Team and Department of Radiation Oncology and Department of Radiation Oncology.
authors.forename: E J
authors.initials: EJ
authors.lastname: Wu
authors.affiliation: Medicine.
authors.forename: Z
authors.initials: Z
authors.lastname: Zhang
authors.affiliation: Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: A
authors.initials: A
authors.lastname: Noy
authors.affiliation: Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Portlock
authors.affiliation: Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: D J
authors.initials: DJ
authors.lastname: Straus
authors.affiliation: Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
authors.forename: A D
authors.initials: AD
authors.lastname: Zelenetz
authors.affiliation: From the Lymphoma Disease Management Team and Department of Radiation Oncology and Department of Radiation Oncology. Electronic address: yahalomj@mskcc.org.
authors.forename: J
authors.initials: J
authors.lastname: Yahalom
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult